Sandoz Launches Enzeevu Biosimilar in U.S.

The 2 mg aflibercept pre-filled syringe enters the U.S. market as Sandoz expands its eye-care biosimilar portfolio.

Updated on Nov. 16, 2026 in Healthcare

Sandoz Launches Enzeevu Biosimilar in U.S.

Sandoz has launched Enzeevu (aflibercept-abzv) 2 mg pre-filled syringe in the United States, a biosimilar approved for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic retinopathy and macular edema. The company also entered a multi-year private-label agreement for the product, with manufacturing beginning in mid-2027.

Why it matters

Enzeevu is approved in the same dosage form, route, and presentation as Regeneron's Eylea, giving U.S. retina patients and providers another option in a market Sandoz estimates at $9.6 billion. Sandoz states that treatment cost remains a significant barrier to care for many patients.

Enzeevu's 2 mg dose is approved for conditions affecting about 30 million Americans, within an estimated $9.6 billion U.S. anti-VEGF market. Pricing relative to Eylea and early uptake figures have not been disclosed.

The players

Sandoz

Sandoz is a Swiss-headquartered generic and biosimilar drugmaker that has expanded aggressively into ophthalmology biosimilars.

Regeneron

Regeneron is a New York-based biopharmaceutical company whose drug Eylea (aflibercept) is the reference product for Enzeevu.

The details

Sandoz received FDA approval for Enzeevu in August 2024 and has now launched the product in the United States with a 2 mg pre-filled syringe. The company also plans manufacturing for a private-label agreement starting mid-2027, and it previously acquired U.S. biosimilar Cimerli and launched Afqlir in Europe in 2025.

Timeline

  1. August 2024: FDA approves Enzeevu.

  2. 2024: Sandoz acquires Cimerli (ranibizumab-eqrn).

  3. 2025: Sandoz launches Afqlir (aflibercept) in Europe.

  4. November 16, 2026: Enzeevu U.S. launch is announced.

  5. Mid-2027: Private-label Enzeevu manufacturing begins.

Market Landscape

The Enzeevu launch extends the wave of aflibercept biosimilar competition that will challenge Regeneron's Eylea as its exclusivity erodes. Sandoz is building a broader ophthalmology position through its Cimerli acquisition and its Bio100 target of more than 100 biosimilars by 2040.

Patients with retinal disease may gain a lower-cost biosimilar option as Enzeevu enters the market, though actual out-of-pocket costs will depend on insurance coverage. Doctors and pharmacies will decide how the product is stocked and prescribed.

The takeaway

Biosimilar competition is steadily reshaping the cost of retina care, and patients may benefit from asking their doctor whether a lower-cost option is appropriate. Expanding supply can help keep long-term treatment more sustainable.

Further reading

Explore more Healthcare coverage on drug pricing, biosimilars, and access to specialty treatments.

Source note: This article includes information reported by Drug Store News.